Introduction
Cardiac complications after noncardiac surgery represent a major population health problem. In a large study in noncardiac surgical patients aged 45 years with atherosclerosis or at risk for it, myocardial infarction was found in 5% and troponin release in 8% of patients. 1 In a noncardiac surgical population with documented coronary artery disease (CAD) or at high risk for it, we have previously found troponin elevation in 16% and myocardial ischemia in continuous electrocardiography (cECG) in 46% of patients. 2 Multiple studies have reported an independent association between postoperative myocardial ischemia and major adverse cardiac events (MACE) and mortality, both short-and long-term. [1] [2] [3] The estimated global volume of surgical procedures amounts to 200 million per year. 4 As such, every year millions of patients may suffer a perioperative myocardial ischemia after noncardiac surgery, and even more patients are at risk for future cardiac events.
There is extensive evidence from animal studies supporting a protective preconditioning effect of volatile anesthetics on ischemic myocardial injury. [5] [6] [7] In patients undergoing coronary artery bypass graft (CABG) surgery, there is some preliminary but inconsistent evidence suggesting clinically relevant preconditioning by volatile anesthetics. [8] [9] [10] Volatile anesthetics significantly reduced troponin release in a meta-analysis of 32 randomized controlled trials (RCT); however, the results showed relevant heterogeneity. 10 Further, the results were not conclusive regarding mortality. A systematic review and meta-analysis that included studies comparing sevoflurane vs. total intravenous anesthesia (TIVA) during CABG surgery found similar results for on-pump CABG but did not detect a preconditioning effect of sevoflurane in off-pump CABG patients. 9 In contrast, Landoni and coworkers 8 found a significant reduction of inhospital mortality and inhospital myocardial infarction without heterogeneity in their metaprocedures amounts to 200 million per year. 4 As such, every year millions of pat atie i ient nt n s ma ma may y y su su suff ffer a perioperative myocardial ischemia after noncardiac surgery, and even more patients are at risk fo or r fu fu futu tu ture re c c car ard diac ac c e e eve v nts.
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Based on this preliminary but promising evidence in patients undergoing on-pump CABG surgery, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines 11 recommend the use of volatile anesthetics as beneficial in hemodynamically stable patients at cardiovascular risk undergoing noncardiac surgery (Class IIa recommendation).
However, data on myocardial preconditioning by volatile anesthetics during noncardiac surgery are scarce. A systematic review failed to retrieve studies with data on perioperative myocardial ischemia in patients undergoing noncardiac surgery, 12 and a small RCT 13 published in the meantime did not detect any protective effect of volatile anesthestics on cardiovascular endpoints in noncardiac surgical patients.
The objective of the Trial on the Effect of Anesthetics on Morbidity and Mortality
(TEAM) (NCT00286585) was to evaluate the hypothesis that anesthesia maintenance with sevoflurane compared to propofol reduces the incidence of myocardial ischemia in patients at cardiovascular risk who undergo major noncardiac surgery.
Methods

Study Design
After approval from the local ethics committee (Ethikkommission beider Basel), we conducted a parallel RCT with fixed 1:1 allocation at a tertiary care center, the University Hospital Basel, to November 2007), Switzerland. We used a computer-generated random allocation sequence stratified by site and by -blocker intake without randomization blocks (see Limitations).
n noncardiac surgical patients.
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Allocation concealment occurred by numbered, sealed, opaque envelops. Research personnel enrolled the patients after the preoperative visit by the anesthetist to ensure that general anesthesia was the planned technique. Randomization took place shortly before surgery. Patients, laboratory personnel, outcome adjudicators, and data analyzers were blinded to allocation.
Anesthesiologists were not blinded, because they could easily guess allocation even when using a double dummy.
Eligibility Criteria
Patients scheduled for surgery under general anesthesia were eligible if they either 1) had proven CAD and were scheduled for major surgery or 2) had two or more risk factors for CAD and were scheduled for major vascular surgery.
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We excluded patients in case of: 1) current medication with sulfonylurea derivatives 16 or theophylline 17 unless stopped 2 days before surgery, as these drugs reportedly inhibit anesthetic preconditioning; 2) current congestive heart failure; 3) current unstable angina pectoris; 4) preoperative hemodynamic instability, defined as the use of vasopressors; 5) hepatic disease, defined as ALAT and/or ASAT values >100 U/L; 6) renal insufficiency, defined as creatinine clearance <30 mL/min; 7) emergent surgery; 8) severe chronic obstructive pulmonary disease, defined as FEV1 <1 L; 9) prior enrollment in the study; 10) concurrent enrollment in another RCT; 11) pregnancy; or 12) absence of written informed consent.
Intervention
The study protocol mandated anesthesia induction with etomidate in all patients and anesthesia maintenance with the allocated drug (sevoflurane or propofol). The agent was started immediately after anesthesia induction and confirmation of the correct tube position. In accordance to the pragmatic purpose of the study, the protocol did not regulate dosage for the induction or maintenance of anesthesia, or any other aspects of the intraoperative management.
Thus, the anesthesiologist in charge was not limited in the decision of choice and dosage of opioids, muscle relaxants, fluids or transfusion of blood products, and choice of vasopressor, if any. Also, extent of perioperative monitoring, type of postoperative analgesia, and specifics of postoperative care were at the discretion of the attending physicians.
Outcomes
The predefined primary endpoint was a composite of any ischemic episode, as detected by 3-lead cECG and/or by troponin T elevation on postoperative days 1 and 2. The definition of ischemia by cECG followed the guidelines for cECG interpretation and required a ST-segment deviation of 1 minute duration. 18 The study protocol mandated anesthesia induction with etomidate in all patients a a and nd d a ane n nest st sthe he hesi sia a maintenance with the allocated drug (sevoflurane or propofol). The agent was started m mm me medi di di t at atel el ely y y a afte e er r r a an anesthesia induction and conf f fir ir irm m mation of the co o orr r ec ct t t tu tu tube b position. In ac cco o ord r ance to o th th he e p pr prag ag gm ma mati ti tic c pu pu purp rpos os ose e e o of of t the s stu u udy, , , t th he pr pr prot oto o ocol ol o d d did id n not ot re eg gul ul lat at te e do do osa a age ge fo or or t the he h n ndu du duct ct ctio io i n n or or or m mai aint nten ena an anc ce ce o of f an an a es es esth th the es esia ia a, , or or or a a any y y o ot the he her r a as aspe pe pect ct cts s of of of t t the he e i i int nt n r r rao op oper er rat at tiv iv i e e m m mana na age ge geme me ent nt t.
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Monitoring and Methods of Follow-up and Outcome Adjudication
Three-lead cECG monitoring (Schiller MT 100 or Schiller MT 101, Schiller Reomed AG, Baar, Switzerland) was applied shortly before anesthesia induction and recorded for 48 hours. The leads were an inferior lead, V5, and an inverse Nehb J lead. 22 Troponin T and NT-proBNP were measured before induction of anesthesia and on postoperative days 1 and 2. A 12-lead ECG was recorded preoperatively and on postoperative day 7 or on the day of hospital discharge, myocardial infarction, or ST-elevation MI. 20 Congestive heart failure requiring ho ho osp p pit ital al aliz iz izat at atio io ion n was defined as hospitalization in consequence of clinical (respiratory rales, S3, jugular venous di ist st ten en ensi si sion on n) ) ) an an nd ra ra rad di diological signs (vascular redi ist st stri rib bution, intersti ti iti t t al p p pul ul ulm monary edema, and al lve e eol o ar edema ma) ) ) of f f h hea eart t t f f fai ai ailu lu ur re re.
Te Tert rt rtia ia iary ry e e en nd dpo po oin in nts ts w we er ere e po po post st stop op per er rat at ativ iv ive de de d li li iri ium um m ( (ac ac acc co cord rd rdin in ng g to to to t th h he C Con on nfu fu fusi sion on on A As s sse es essm sm men n nt t 21 21 21 p p pos os osto to t pe pe era ra rati t t ve ve ve n nau au ause e ea a a an an and d d vo vo vomi mi miti ti t ng ng n ( ( (PO PO PONV NV NV) ) ), , , an an nd d d pa pa pati ti tien en ent t t sa sa ati ti isf sf sfac ac acti ti tion o . Patient whichever occurred first. Research personnel visited the patients shortly after surgery and on postoperative days 1, 2, and 7 to ensure compliance with the cECG and troponin monitoring and to assess CAM, PONV, and overall patient satisfaction. Patient satisfaction was assessed using a numeric rating score (NRS) with a range from 0 to 10, the latter indicating highest satisfaction.
Blinded research personnel contacted the patients by phone 6 and 12 months after randomization.
If patients reported an event after discharge, the research personnel contacted their treating physicians to obtain appropriate documentation.
Two trained, blinded investigators independently analyzed the cECG and adjudicated on myocardial ischemia as defined by the ACC/AHA guidelines for interpretability of cECG 18 from computer analyzer-processed cECG recordings (Schiller MT 200 Schiller Reomed AG, Baar, Switzerland). Inconsistencies were resolved by discussion. The ACC/AHA guidelines for the interpretability of cECG recommend that the cECG recordings fulfill a set of 12-lead ECG-and medication-based criteria and of cECG-based criteria to be considered suitable for STmonitoring. 18 As adherence to the cECG-based interpretability criteria has been shown to not improve the association between cECG-based ischemia and outcome at 12 months, 23 we analyzed all cECG for ST-monitoring that fulfilled the 12-lead ECG and medication-based criteria. Blinded research personnel entered all cECG data in the database in duplicate.
All blood samples were analyzed centrally at the laboratory of the University Hospital
Basel. Laboratory personnel were blinded to allocation and were unaware of the study question. Research staff previously trained by a neuropsychologist assessed the occurrence of delirium by the CAM at baseline, on postoperative day 1, 2, and 7 or on the day of hospital discharge, whichever occurred first. Postoperative delirium on postoperative day 1, 2, or 7 was defined as a CAM suggestive of delirium according to the interpretation algorithm published by Inouye and coworkers.
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Statistical Analysis
The sample size estimation (n=187 per arm) was based on an event rate of 46% for myocardial ischemia in cECG 2 in the control group, a relative risk reduction of 30%, 10, 25 a 2-sided alpha 0.05, and power of 80% in the chi-squared test.
The statistical analysis followed a prespecified analysis plan and was conducted blindly.
We applied a 2-sided alpha=0.05 for statistical significance. All calculations were performed Two blinded investigators independently adjudicated all cardiac events du du uri ing ng n f f fol ol ollo lo low-w-w up up 12 months after surgery. Blinded research personnel entered all the events in the database in du upl pl plic ic icat at ate e.
Re R search s sta ta aff f f p pre re evi vi iou ousl sl sly y y tr trai ai ine ne ned d by by y a n n neu u urop p psy y ych ho hol lo log gi gist t t a as ss se es sse sed d As primary efficacy analysis, we conducted an intention-to-treat analysis of the incidence of the composite of myocardial ischemia, as detected in the cECG and/or by troponin elevation in each group by chi-squared test. Supportive efficacy analyses included the comparison of the secondary endpoints by chi-squared test, of time to MACE by log-rank test, and of differences in the distribution of postoperative NT-proBNP by Mann-Whitney U-test.
Further, we compared the incidence of delirium on days 1, 2, or 7 and of PONV on days 1 and 2 by chi-squared test (tertiary endpoint). We tested for differences in the NRS score distribution by Mann-Whitney U test (tertiary endpoint).
Finally, post-hoc, we assessed the impact of the troponin assay (4 th and 5 th generation troponin) on the primary endpoint by chi-squared test for heterogeneity. We did not model missing data but assumed that missing cECG, troponin T, and 12-lead ECG did not demonstrate ischemia.
Results
We enrolled 385 patients between February 2006 and October 2010 (Figure 1) . Seventeen patients (4.4%) were erroneously randomized. In 2 patients (both in the sevoflurane group), sulfonyl urea intake was recognized after randomization, and 15 other patients . W We We t tested for diff fer er e ence ce es s s in i the NRS score d di dist t tri ribution by y Ma Ma Mann n-W -W -Whi hi hitn tn tney ey ey U U te te t s st st ( ( (te e ertia ary ry end d dp po oin n nt) t) t). .
Fi Fina na all ll lly, y, p p pos s st-t-h ho hoc, c, c, w we e as asse se sess ss sse ed ed t t th he e e im im impa pa act ct c o of f f th th he e tr tr trop op opon on nin in n a ass ss ssay ay ay (4 4 4 th th a a and nd nd 5 5 th th g g gen ne e era at atio ion n n roponin) on n t t the he he p p pri ri rima ma mary ry y e end nd ndpo po p in in int t t by by by c c chi hi h -s -s squ qu quar ar are ed d d te te t st st s f for or or h h het et eter er erog og ogen n ne e eit it ity. y. y. W W We e e di di did d d no no not t t mo m m del creatinine clearance of <30 mL/min. Three patients (0.8%) underwent minor surgery instead of the planned major procedure. The data of all of these patients were included in the intention-totreat analysis. One patient (0.5%) allocated to propofol received both propofol and sevoflurane.
Cross-over did not occur. The unequal number of patients allocated to sevoflurane and propofol was a consequence of the use of an allocation sequence without randomization blocks (see Limitations). 
Cardiovascular Endpoints
The primary composite endpoint occurred in 75 patients (40.8%) after sevoflurane and 81 (40.3%) after propofol ( Table 2) . There was no evidence of heterogeneity in either the results of the primary composite endpoint (test for heterogeneity, p=0.407) or of troponin T elevation (test for heterogeneity, p=0.291) based on the troponin T assay. There were no sex-based differences (test for heterogeneity, p=0.560). None of the cardiovascular secondary endpoints differed between treatments ( Table 2) .
Fourteen patients (7.6%) allocated to sevoflurane and 17 patients (8.5%) allocated to cECG was missing in 10 patients (2.6%), 4 (2.2%) in the sevoflurane gro oup u up a and nd nd 6 6 6 ( ( (3% 3% 3%) ) in he propofol group. Agreement in the cECG adjudication was high, ( =0.85; observed agreemen 0. .92 92 2; ; 95 95 95% % % CI CI CI, 0. .89 89 89-0 -.95). Troponin data on both h h po po ostoperative da a ay y y 1 an an and d d 2 were missing in 7 pati i ien e ts (1.8% %) ), 3 (1. 1 6% 6% 6%) ) ) in in in t t th h he e se se evo vo vofl flur ur rane e an an nd 4 4 4 ( (2%) %) %) i in n th th t e e pr pr rop p pof of fol ol o g g gro roup up up. . In In n n no on one e of of f t the he he pa pati ti tien en nts ts t w wer er ere e e bo both th t tro ropo po oni nin n v va valu lu lues es es a a and nd d t the he he c cE cECG CG C re ec eco or ordi di ding ng ng m m mis is i s s sing ng ng. T Tw Twel el e ve ve e-m -m mon on nth th h fo ol ollo o ow-w-u up up could be obt tai ai ine ne ned d d fo fo for r al al all l pa pa ati ti tien en e ts ts ts. .
propofol suffered the composite endpoint of MACE at 12 months (log-rank test, p=0.772) ( Table   2 , Figure 2 ). All-cause mortality at 12 months was 12.5% and did not differ between the two groups ( Table 2 ). The cause of death could not be clarified in 3 patients (6%). Death of unknown cause was considered to be noncardiac as prespecified. Ten patients (2.6%) suffered a cardiac death ( Table 2) .
We performed a per-protocol analysis excluding the 17 erroneously included patients and 3 patients that underwent minor surgery instead of the planned major procedure. Seventy patients (40.2%) in the sevoflurane and 76 patients (39.8%) in the propofol group suffered the primary endpoint (p=0.932). In the per-protocol analysis, MACE at 12 months occurred in 6.3% (11/174) and 6.8% (13/191) patients in the sevoflurane and propofol group, respectively (p=0.772). In an analysis excluding the patients with preoperatively elevated troponin the relative risk (RR) for the primary endpoint was 1.07 (95% CI, 0.80-1.43).
Other Endpoints
The incidence of delirium did not differ between groups (Table 3) . PONV was more frequent after sevoflurane anesthesia on postoperative day 1. However, this difference in PONV did not persist on day 2 after surgery ( Table 3) .
Patient satisfaction was systematically assessed in 2 of the 3 study centers (n=284). The NRS distribution did not differ across the two groups at any time-point (Table 3) .
Discussion
In the present trial, anesthesia maintenance with sevoflurane compared to propofol did not reduce the incidence of perioperative myocardial ischemia in high-risk patients undergoing major noncardiac surgery. In addition, our study did not suggest any effect of sevoflurane on and 6.8% (13/191) 
patients in the sevoflurane and propofol group, respectively ( (p p p ( ( ( ( =0 =0 0.7 7 772 72 72). ). ). I I In n n an a analysis excluding the patients with preoperatively elevated troponin the relative risk (RR) for
h he e pr pr prim im imar ar ry y y e en ndp p poi oi oint n was 1.07 (95% CI, 0.80-1. 4 43 43) ).
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Perioperative myocardial ischemia occurs frequently after noncardiac surgery. for <12-month mortality and 1.8 (95% CI, 1.4-2.3) for >12-month mortality. The independent association of postoperative troponin elevations independent of ischemic symptoms was reported for 30-day mortality, 1 and the population-attributable risk of postoperative elevated troponin for 30-day mortality was quantified at 42% in over 15,000 patients. Presence or absence of ischemic symptoms was not considered in this last analysis. 31 In the present trial of patients at high cardiovascular risk, the incidence of troponin elevations within the first two days after noncardiac surgery was 26.7%. This estimate was consistent with reported incidences in patients at cardiovascular risk undergoing noncardiac surgery. 15, 32, 33 In spite of the incidence of perioperative myocardial ischemia, little progress has been made in its prevention over the last decade, and there is still no established efficacious and safe prophylaxis for perioperative myocardial ischemia. Animal models of myocardial ischemia [5] [6] [7] suggest pharmacological preconditioning by volatile anesthetics as a potential approach for prevention of perioperative myocardial ischemia. Further, the administration of volatile morbidity and mortality. However, data on the effect of volatile anesthetics on perioperative risk in noncardiac surgical patients were not available at that time and still are scarce. A secondary, retrospective analysis of data obtained in a phase II study in 784 vascular surgical patients at cardiac risk failed to detect an effect of volatile anesthetics on troponin release and incidence of postoperative cardiac events when compared to propofol. 34 A recent small prospective and randomized study of sevoflurane vs. propofol also did not detect any difference in the incidence of troponin elevation in 88 patients with CAD undergoing thoracic or vascular surgery. 13 The results of our adequately sized randomized controlled trial did not detect an effect of volatile anesthetics on perioperative ischemia in noncardiac surgical patients with CAD or at risk for it. It was, thus, in agreement with the preliminary results of the two previous studies.
In patients undergoing valvular cardiac surgery, data are scarce and do not support a protective effect by sevoflurane. 35 The results of studies investigating the effects of volatile anesthetics on perioperative ischemia and postoperative cardiac events in patients undergoing CABG surgery are inconsistent. The largest multicenter RCT in patients undergoing on-pump CABG surgery allocated a total of 414 patients to sevoflurane vs. desflurane vs. TIVA, but did not detect any difference in postoperative troponin release 36 between the groups. In contrast, a previous systematic review and meta-analysis that focused on studies comparing sevoflurane vs.
TIVA during CABG surgery suggested reduced troponin release and improved cardiac index in the sevoflurane group. These results, however, showed significant heterogeneity. 9 Another metaandomized study of sevoflurane vs. propofol also did not detect any difference in in n t t the he h i i inc c ncid id iden en e ce c of troponin elevation in 88 patients with CAD undergoing thoracic or vascular surgery. r 13 The e esu su ult lt lts s s f of of o o our ur u ade de eq qu quately sized randomized contr tr ro o oll le ed trial did not ot t det tec ec ect t t an effect of volatile an nes s esth t etics on n p pe e eri i iope pe era ra ati ti tive ve e i i is sc sche hemi mi mia a in in non n nca a ardi ia ac c c su u urg rg rgic ica al a p pat ati i ien nt nts s w wi w t th h C C CAD AD A o o or r r a at at r ris i i k k k f fo for r r i it it. I wa wa as, s, s, t t thu hu h s, s, s, i i in n n ag agr re ee em emen en nt t wi with h h t the he he p p pre re reli lim mi min n nar ar ary y y re re resu su sul lts s s of f f t the he he t t two wo wo p p pre revi vi viou ou us st stud ud die ie es. s. s analysis including any volatile anesthetics during CABG surgery also found reduced troponin release after administration of a volatile anesthetic in the pooled results. However, significant heterogeneity affects the validity of these results as well. 10 Data suggesting an effect of volatile preconditioning on the incidence of postoperative cardiac complications rely on a very limited number of events in CABG patients and are inconsistent. One metaanalysis assessing sevoflurane or desflurane vs. TIVA during cardiac surgery of mostly CABG patients reported a reduced incidence of inhospital fatalities and inhospital myocardial infarction. 8 In contrast, two other metaanalyses 9, 10 and a large multicenter RCT 36 published more recently failed to reproduce these findings.
Overall, there are some data suggesting a clinically relevant preconditioning effect of volatile anesthetics in patients undergoing on-pump CABG surgery, although these results are conflicting and open to diverging interpretations. 37, 38 In contrast, there are no data suggesting a clinically relevant preconditioning effect of volatile anesthetics outside the CABG surgery setting. The present, adequately sized RCT as well as a previous small study 13 failed to detect a clinically relevant effect of volatile anesthetics on the incidence of perioperative myocardial ischemia in noncardiac surgical patients at coronary risk. This growing evidence questions the recommendation to preferentially use volatile anesthetics in noncardiac surgical patients at cardiac risk, 11 because volatile anesthetics are also associated with specific adverse effects. 39 Several potential explanations have been proposed for the divergence of animal and clinical data.
Researchers hypothetized that the non-transferability of the promising animal results to the clinical setting may depend on co-medications, age, and comorbidities that attenuate the preconditioning response. 38 The inconsistent results during on-pump CABG surgery may arise from varying protocols particularly in terms of continuous vs. intermittent aortic cross-clamping, Overall, there are some data suggesting a clinically relevant preconditioni ni ing ng g eff ff ffec c ect t t of of of volatile anesthetics in patients undergoing on-pump CABG surgery, although these results are co onf nf nfli li lict ct cti in ing g g an an nd op op ope en en to diverging interpretations. s. s 37, 3 37, 38 In contrast, th t t er re e e a ar are no data suggesting a cl lin n nic ically relev van an nt pr rec econ on ondi di diti ti ion on onin ing g g e ef eff fe ec ct t of f vo o olati i ile e e an ne nes st sthe he eti i ics cs o ou ut utsi side de de t the he C C CA AB ABG G G s su surg rg ger er ry y e ett tt ttin in ing g. g. T The he e p p pre res sen nt nt, , a ad adeq eq equ uate te tely ly y s s siz iz ized e ed RC RC RCT T T as as a w w we el ll a as a a p p pre re revi viou ou ous s s sm sm mal al a l l l st t tud udy y y 13 3 3 f fai ai ile le led d d to to o d d det ete ec ct a a clinically rel lev ev van an a t t t ef ef effe fe ect ct t of f f vo vo vola a ati ti t le le l a a ane e est st s he he heti ti t c c cs s on on n t t the he h inc nc ncid id iden en ence ce ce o o of f pe pe peri ri riop op oper er erat ativ iv ive e e my my myoc oc o ardial which in itself may induce preconditioning secondary to repeated ischemia and reperfusion stimuli (ischemic preconditioning). 36, 40, 41 Our finding of similar NT-proBNP release in both groups is consistent with the similar incidence of ischemia, because ischemia and volume overload causing wall stress are triggers of natriuretic peptide release. 42, 43 Delirium is an unsolved problem after major surgery. The pathophysiological mechanisms of delirium have not been elucidated. Animal data have demonstrated neuroprotection to ischemia by exposure to volatile anesthetics. 44, 45 Preliminary human data suggest that inhalational anesthetics may be associated with better short-term cognitive performance after on-pump CABG surgery. 46, 47 In contrast, the incidence of delirium did not differ between the desflurane and propofol groups. 46 In the present trial, we also did not detect an influence of the volatile anesthetic sevoflurane on the incidence of delirium.
Major cardiovascular complications and deaths did not differ in larger trials, which randomized patients to combined anesthesia techniques. [48] [49] [50] The results of this trial may, thus, be viewed in the broader evidence-context suggesting that the applied anesthetic technique may not play a major role on the occurrence of major cardiovascular complication and death after noncardiac surgery.
Strengths and Limitations
The validity of our results is supported by a randomized design and a blinded cECG analysis with high inter-reader agreement. We achieved complete follow-up at 12 months, and all events were adjudicated independently by two blinded investigators. Further, prognostic balance at the end of the trial was maintained by an intention-to-treat analysis. In addition, the statistical analysis followed a predefined analysis plan and was performed by a blinded data analyst.
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Extensive consistency checks and duplicate entry of all endpoint data supported high data quality.
We are aware of the following limitations: first, we renounced using a double-dummy approach, because it was not clinically feasible to reliably blind the anesthesiologists. However, outcome assessment and adjudication (cECG, troponin T, NT-proBNP measurement, 12-lead ECG analysis, and long-term follow-up) occurred blindly. A second limitation is the switch from 4 th to 5 th generation troponin T assays during the study period. However, we did not detect any interaction by troponin assay. A third limitation resulted from the erroneous enrollment of a small number of patients with a creatinine clearance <30 mL/min. We included the data of these patients in the analysis, as per intention-to-treat. The number of patients with reduced creatinine clearance did not differ between groups. Therefore, we do not expect that the inclusion of these patients might have biased our findings. Further, none of the endpoints differed in the perprotocol analysis excluding erroneously randomized patients. Forth, the sample size of the study was powered to compare the incidence of perioperative ischemia (ie, the primary endpoint and not for comparing postoperative cardiac events). Therefore, the interpretation of MACE results warrants caution. If current findings are used as pilot data for calculating the sample size to compare the incidence of MACE, more than 14,000 patients are needed to achieve a power of 80%. As our data do not suggest any relevant anesthetic preconditioning effect at the myocardial damage level (ie, at the level of the assumed pathophysiological link between preconditioning and outcome), we consider realization of such a large trial as not justified. A final limitation is that we did not use randomization blocks, which resulted in a larger number of patients allocated to propofol than sevoflurane.
Conclusions
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